Cargando…
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study
CORT125134 is an orally active, high‐affinity, selective antagonist of the glucocorticoid receptor that is being developed for indications that may benefit from the modulation of cortisol activity. This first‐in‐human study was conducted to evaluate the dose‐related safety, tolerability, pharmacokin...
Autores principales: | Hunt, Hazel, Donaldson, Kirsteen, Strem, Mark, Zann, Vanessa, Leung, Pui, Sweet, Suzanne, Connor, Alyson, Combs, Dan, Belanoff, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947602/ https://www.ncbi.nlm.nih.gov/pubmed/28967708 http://dx.doi.org/10.1002/cpdd.389 |
Ejemplares similares
-
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
por: Hunt, Hazel J., et al.
Publicado: (2021) -
An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes
por: Custodio, Joseph M., et al.
Publicado: (2020) -
Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers
por: Pawsey, Stephen, et al.
Publicado: (2016) -
Cortés según Cortés
por: Sotomayor, Arturo
Publicado: (1979) -
Cortés.
Publicado: (1969)